Purpose: Oxaliplatin (L-OHP), a new platinum analogue, is an active drug in colorectal and ovarian cancer. In this phase II study we explored tolerability and activity of oxaliplatin as a single agent in metastatic breast carcinoma patients.
Introduction
Breast cancer is the most frequent neoplasm in women in European countries. Not withstanding the increasingly widespread use of adjuvant chemotherapy, about 60% of the patiens will ultimately develop distant metastases. Conventional treatments have no curative impact on advanced disease, with a median survival of about two years after evidence of metastases. The treatment of advanced breast cancer is still complex and partly controversial, as there is still no universally accepted therapy [1] . Anthracyclines (doxorubicin and epirubicin) and more recently taxanes (paclitaxel and docetaxel) and vinorelbine are the most active agents in this disease and are now commonly used as front-line therapy. Therefore the discovery of new active drugs, as well as the exploration of new combinations and schedules of drugs with proven efficacy, is clearly needed. Oxaliplatin (L-OHP), a new platinum analog, is a water-soluble compound with an oxalate ligand and 1,2 diaminocyclohexane (DACH) carrier [2] . The mechanism of cytotoxicity is the formation of platinated intrastrand adducts leading to inhibition of DNA synthesis. L-OHP differs from cisplatin and carboplatin by its toxicity profile with absence of renal and auditor toxicities and minimal myelosuppression. The dose-limiting toxicity of oxaliplatin is a cumulative peripheral sensory neuropathy [3] . The antitumoural activity has been observed in colorectal, ovarian, lung and head & neck carcinomas. Occasional responses have been observed in advanced breast cancer patients during phase I studies [4, 5] . Therefore it was reasonable to explore the activity and tolerability of L-OHP in pretreated patients with metastatic breast cancer. At the time the study was designed taxanes were not on the market and therefore these patients were all pretreated with anthracyclines but they were taxanesnaive. This is the first reported experience on the activity of this drug as a single agent in breast cancer.
Patients and methodŝ legibility criteria
From January to September 1994 14 patients with melastatic breasl cancer were entered into the study. The study was approved by the Ethical Committee of the Regina Elena Cancer Institute and an informed consent was given by all the patients.
Elegibility criteria included the following: histologically proven diagnosis of breast cancer with at least one bidimensionally measurable or evaluable metastatic lesion, life expectancy > 3 months, age between 18 and 75 years; performance status (PS, Eastern Cooperative Oncology Group (ECOG) scale) 0-2 Other requirements were adequate bone marrow function (absolute neutrophil ^2000 mm 3 ; platelet count 3= 100,000 mm 3 , haemoglobin > 10 g/dl). acceptable liver and renal function (bilirubin and transaminase value not worse than 1.5 time the upper limit of normal, blood creatinine <2 mg/dl) and adequate cardiac function. All patients had to receive prior chemotherapy with anthracycline-containing regimen in the adjuvant or the metastatic setting, completed at least four weeks before beginning the new treatment. Prior hormone therapy was allowed, as well as prior radiotherapy provided that at least four weeks had elapsed since the last treatment and no more than 20% of the bone marrow reserve had been irradiated Irradiated lesions were not used for response assessment, unless clearly progressive. Patients with brain metastases, pulmonary carcinomatous lymphangitis, neoplastic ascites and/or pleural effusion as the only site of disease were not considered elegible. Other exclusion criteria included inadequate bone marrow reserve and renal or cardiac insufficiency.
Pretreatment assessment and follow-up
At entry to the study, each peatient was given a complete physical examination, a battery of laboratory tests including CEA and CA15.3. and underwent radiological studies (conventional X-ray films, ultrasound and bone scan, plus CT scans when needed). Patients underwent complete physical examination and biochemical profile before each treatment.
Treatment regimen
L-OHP was administered at the dose of 130 mg/m 2 diluted in 500 ml of 5% glucosate solution in two-hour infusion. The courses were repeated every three weeks. Emesis was prevented with 8 mg of ondansetron plus 8 mg of dexamethasone i.v. before chemotherapy. The drug was supplied directly by Debiopharm S.A., Lausanne, Switzerland. Toxicity and dose modification Toxicity was assessed by WHO criteria [6] for haematological toxicity of grade 2 or more, treatment was interrupted until WBC was restored to 2500 mm 3 and the neutrophil count was better than 1500 mm 3 . With non-haematological toxicity in excess of grade 2. treatment was suspended until recovery to < grade 1.
Response criteria WHO criteria were used to evaluate response. Criteria used to define a complete response of bone metastases were the disappearance of all osteolytic lesions, normalized bone scan for at least four weeks, and no need for pain medication. A partial response was defined as improvement or stability of X-ray pictures with reduced intensity and number of high-uptake areas in scintiscan, allevation of bone pain allowing at least 50% reduction of analgesic dosages, and an improvement in performance status by at least one grade for at least four weeks.
The objective response was evaluated every two cycles of treatment by repeating the same investigations performed before starting it. Patients who received at least one cycle of therapy were to be considered in the survival and toxicity analysis. Response duration was defined as the interval between the start of treatment and progression time and survival was calculated from the first day of treatment to the day of death or the last available follow-up.
Statistical analysis
The dose intensity (DI, mg/m 2 /week) was calculated as previously described by Hryniuk. Response duration, progression-free and overall survival were calculated according to the Kaplan-Meier method.
Results
All 14 patients were evaluable for toxicity and activity. Patient characteristics are given in Table 1 . Patients who had progressed during treatment with anthracyclines were defined as anthracycline-refractory. Patients who had progressed within six months from the completion of an anthracycline-containing adjuvant regimen, or had SD as the best response to anthracycline-containing regimen for metastatic disease, were defined as resistant. The remaining patients were considered anthracycline-sensitive. Anthracycline-refractory and resistant patients were considered together in the response analysis. All patients received at least two cycles of treatment (median 4, range 2-6). The main reason for treatment discontinuation was progressive disease (nine patients, 64%). Median delivered L-OHP dose-intensity (DI) was 43.3 mg/m 2 /week (range 32.5-43.3) which is equivalent to the 100% of projected DI.
Toxicity
All the 14 patients were assessable for toxicity for a total of 50 courses. Treatment was generally well tolerated and no dose reductions were required; no grade 3-4 toxicity was present (Table 2) . Peripheral neurosensorial toxicity graded according to a specific scale [7] did not (94) 14 (100) 50 (100) 12 (86) 48 (96) 7 (50) 32 (64) 13 (93) 47 (94) 14 (100) 50 (100) 14 (100) 50 (100) 6 (43) 32 (64) 14 (100) 50 (100) Grade 1 1 (7) 1 (2) -1 (7) 1 (2) 2 (14) 12 (24) 1 (7) 3 (6) 4(28.5) 8(16) _ -Grade 2 1 (7) 2 (4) --1 (7) 1 (2) 5 ( 
Response to treatment
Three objective partial responses were obtained, 21% (95% CI: 0%-43%). The three responses were obtained in a patient with liver metastases as dominant site of disease, in a patient with metastatic lymphonodes and in a patient with bone lesions. These three responses were obtained in the group of patients defined as refractory/ resistant to anthracyclines. No complete response was present. Disease stabilisation was achieved in two patients (14%) and nine patients (64%) had progressive disease. Two responses lasted five months and one four months. With a median follow-up of 12 months (range 3-41) median overall survival was 12 months (95% CI: 5-28).
Discussion
Cisplatin (CDDP) is one of the most commonly used anticancer agents with documented activity against a number of solid tumors. Although it is not widely used in the treatment of breast cancer, CDDP has achieved a response rate of 47%-54% in patients with previously untreated metastatic disease, however response rates decrease to approximately 10% in previously treated patients. L-OHP is a third generation platinum compound proved to be active in various tumour types in cell lines, in animals and in human tumours. A high cytotoxic effect, superior to that of CDDP, was observed in vitro in human MCF-7 cell line, and in vivo in the murine MA-16c mammary tumour and in the Gr-mouse mammary model which mimics a hormone refractory breast cancer [8, 9] . Despite the similarity of the adducts produced by CDDP and L-OHP, the study of adducts formation demonstrate that adducts produced by L-OHP are qualitatively and quantitatively different from those produced by CDDP. The DNA mismatch repair system plays an important part in the recognition of CDDP adducts and recent studies have shown that loss of DNA mismatch repair results in resistance to CDDP but not to L-OHP [10] , suggesting that the mismatch repair proteins serve as a detector for CDDP but not for L-OHP adducts. This could explain the difference in cell cytotoxicity between CDDP and L-OHP.
The isolated responses observed in patients with advanced breast carcinoma during phase I trials prompted us to design this trial. We observed activity of L-OHP in this selected population and three responses (21%) were observed in 14 patients considered as refractory or resistant to anthracyclines. This small monocentric trial was prematurely closed due to the introduction of paclitaxel in the current treatment of this disease and consequently patients were treated not only with anthracyclines as first-line therapy.
The results obtained confirm the good toxicity profile of this drug although the assessment of neurotoxicity was not clearly adequate due to the relative limited number of courses delivered, median number being 4. We now know that the peripheral sensory neurotoxicity with functional impairment affects more than 10% of patients when the cumulative L-OHP dose reaches 800 mg/m 2 [3] . It seems obvious that the future development of L-OHP is not as single agent but in combination with other active drugs. The association of L-OHP with 5-fluorouracil (5-FU) and folinic acid, now considered one of the most active regimens in advanced colorectal cancer, as well as L-OHP with the taxanes, are candidates for combinations. Cottu et al. used L-OHP 130 mg/m 2 every three weeks in combination with 5-FU given by continuous infusion in 61 women with advanced breast cancer, all pretreated with anthracyclines ± taxanes obtaining 25% response rate with a median duration of response of 7.5 months [11] . Agelaki et al. gave L-OHP, 90 mg/m 2 every three weeks, with escalating dose of docetaxel in phase I study in breast and lung cancer patients: a 24% response rate was achieved [12] . An EORTC multicentre trial with L-OHP alone is ongoing in pretreated patients with advanced breast cancer and a phase II -III study comparing L-OHP-5-FU to vinorelbine-5-FU in patients with metastatic breast cancer after taxane/anthracycline treatment.
In conclusion L-OHP was proved to display activity in advanced breast carcinoma patients pretreated with anthracyclines with a 21% response rate. The role of this drug in the strategy for the treatment of this disease will be assessed by future trials when it will be used in combination with other active compounds.
